- £1.72bn
- £1.97bn
- £668.80m
- 39
- 12
- 95
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 29.13 | ||
| PEG Ratio (f) | 2.28 | ||
| EPS Growth (f) | 14.68% | ||
| Dividend Yield (f) | 1.33% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.32 | ||
| Price to Tang. Book | 4.96 | ||
| Price to Free Cashflow | 54.86 | ||
| Price to Sales | 2.56 | ||
| EV to EBITDA | 45.32 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.28% | ||
| Return on Equity | -0.73% | ||
| Operating Margin | -0.36% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 551.4 | 574.3 | 593.4 | 689.7 | 668.8 | 673.42 | 699.68 | 6.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +25.19 | +41.28 | -21.01 | +6.02 | -40.88 | +74.58 | +14.68 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genus plc is a United Kingdom-based global animal genetics company. The Company is advancing animal breeding and genetic improvement by applying biotechnology and selling added value products to livestock farming and food producers. It focuses on the dairy, beef and pork food production sectors, through two businesses: ABS (bovine genetics) and PIC (porcine genetics). Its segments include Genus PIC, Genus ABS and Genus Research and Development. Its bovine genetics business sells dairy and beef bull semen and embryos from its superior cattle, which are sold to farmers to breed their cows through artificial insemination. Its porcine genetics business sells genetically superior breeding pigs and semen to farmers, so they can breed commercial pigs with desirable characteristics for pork production. Its porcine and bovine divisions operate under the brand names PIC and ABS. It operates in 30 countries, across six continents, and reaches a further 50 markets through distribution partners.
Directors
- Iain Ferguson NEC (65)
- Stephen Wilson CEO
- Alison Henriksen CFO
- Elena Rice CSO
- Dan Hartley GCN
- Angelle Rosata DHR
- Bill Christianson OTH
- Jerry Thompson OTH
- Nate Zwald OTH
- Jason Chin NID
- Lysanne Gray NID
- Lesley Knox NID
- Lykele van der Broek NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 26th, 1994
- Public Since
- July 6th, 2000
- No. of Employees
- 3,439
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 66,037,454
- Address
- Matrix House, Basing View, BASINGSTOKE, RG21 4DZ
- Web
- https://www.genusplc.com
- Phone
- +44 1256347100
- Contact
- Anand Date
- Auditors
- Deloitte LLP
Latest News for GNS
Upcoming Events for GNS
Preliminary Q4 2025 Genus PLC Earnings Release
Full Year 2025 Genus PLC Earnings Release
Similar to GNS
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 20:47 UTC, shares in Genus are trading at 2,600.00p. This share price information is delayed by 15 minutes.
Shares in Genus last closed at 2,600.00p and the price had moved by +46.73% over the past 365 days. In terms of relative price strength the Genus share price has outperformed the FTSE All Share Index by +34.61% over the past year.
The overall consensus recommendation for Genus is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Genus dividend yield is 1.23% based on the trailing twelve month period.
Last year, Genus paid a total dividend of £0.32, and it currently has a trailing dividend yield of 1.23%. We do not have any data on when Genus is to next pay dividends.
We do not have data on when Genus is to next pay dividends. The historic dividend yield on Genus shares is currently 1.23%.
To buy shares in Genus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 2,600.00p, shares in Genus had a market capitalisation of £1.72bn.
Here are the trading details for Genus:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: GNS
Based on an overall assessment of its quality, value and momentum Genus is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Genus is 2,566.67p. That is 1.28% below the last closing price of 2,600.00p.
Analysts covering Genus currently have a consensus Earnings Per Share (EPS) forecast of £0.78 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genus. Over the past six months, its share price has outperformed the FTSE All Share Index by +33.56%.
As of the last closing price of 2,600.00p, shares in Genus were trading +35.85% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genus PE ratio based on its reported earnings over the past 12 months is 29.13. The shares last closed at 2,600.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genus' management team is headed by:
- Iain Ferguson - NEC
- Stephen Wilson - CEO
- Alison Henriksen - CFO
- Elena Rice - CSO
- Dan Hartley - GCN
- Angelle Rosata - DHR
- Bill Christianson - OTH
- Jerry Thompson - OTH
- Nate Zwald - OTH
- Jason Chin - NID
- Lysanne Gray - NID
- Lesley Knox - NID
- Lykele van der Broek - NID